DaVita Inc.
DVADaVita Inc. is a leading provider of kidney care services in the United States, specializing in the treatment of chronic kidney failure and end-stage renal disease. The company operates a network of dialysis clinics, offering outpatient dialysis services and related healthcare solutions. DaVita focuses on improving patient outcomes through comprehensive care and innovative health programs.
Company News
While Greg Abel has taken over as CEO of Berkshire Hathaway, investment manager Ted Weschler continues to play a significant role in portfolio decisions. Two stocks personally selected by Weschler—DaVita and Sirius XM—have performed exceptionally well in 2026, with DaVita up over 102% and Sirius XM up over 50% year-to-date. This suggests Berk...
Warren Buffett and Greg Abel's Berkshire Hathaway portfolio is notably absent from the healthcare sector, holding only DaVita and recently exiting UnitedHealth Group. The article argues investors should consider healthcare independently, as it offers opportunities across multiple investment styles—from high-growth pharma/biotech plays like Eli ...
U.S. equities hit fresh record highs on May 6, 2026, with the S&P 500 and Nasdaq 100 reaching all-time peaks. AMD and Super Micro Computer surged 16% on strong AI-driven earnings, while oil prices collapsed 6-7% on diplomatic hopes between Washington and Tehran. Technology stocks led gains, though energy stocks declined sharply. Mixed earnings re...
The American Heart Association has introduced the Cardiovascular-Kidney-Metabolic (CKM) Health Initiative to increase awareness of the interconnected nature of heart disease, kidney disease, diabetes, and obesity. Nearly 90% of U.S. adults have at least one CKM risk factor, yet many cases remain undiagnosed. The initiative encourages regular scre...
R1 Therapeutics, a new clinical-stage biopharmaceutical company, launched with an oversubscribed $77.5 million Series A financing co-led by Abingworth, DaVita Venture Group, and F-Prime. The company licensed exclusive global rights (outside Greater China) to AP306 from Alebund Pharmaceuticals, a first-in-class pan phosphate transporter inhibitor ...
